Overview

Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction

Status:
Recruiting
Trial end date:
2022-12-17
Target enrollment:
0
Participant gender:
All
Summary
To determine whether long-term treatment with oral betablocker (BB) therapy after myocardial infarction (MI) in patient with no heart failure reduces the composite outcome of death from any cause, recurrent MI, unstable angina pectoris, stroke or heart failure.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bispebjerg Hospital
Collaborators:
Aalborg University Hospital
Aarhus Universitetshospital
Amager Hospital
Bispebjerg Frederiksberg Hospital
Bornholm Hospital
Central Denmark Region
Danish Heart Foundation
Gentofte Hospital
Glostrup University Hospital, Copenhagen
Herlev Hospital
Holbaek Hospital
Hospital of Southern Jutland
Hospitalsenheden Midt
Hospitalsenheden Vest
Hvidovre University Hospital
Naestved Hospital
Nordsjaelland Hospital
Nordsjaellands Hospital
Nykoebing Hospital
Odense University Hospital
Region of Southern Denmark
Region Zealand
Regionshospitalet Horsens
Silkeborg Sygehus
Slagelse Hospital
Svendborg Hospital
Sydvestjysk Sygehus
Sygehus Lillebaelt (Vejle and Kolding)
The Capital Region of Denmark
The North Denmark Region
The Novo Nordisk Foundation
Zealand University Hospital
Treatments:
Adrenergic beta-Antagonists
Bisoprolol
Carvedilol
Metoprolol
Nebivolol
Criteria
Inclusion Criteria:

- Left ventricular ejection fraction > 40%

- Myocardial infarction (MI) within previous two weeks

The diagnosis of acute MI must meet the Universal European Society of Cardiology (ESC)
definition of MI

Exclusion Criteria:

- Clinical evidence of heart failure at the time of discharge

- Pregnancy or of child bearing age not using safe anticonception throughout the study
period

- Lack of signed informed consent and expected cooperation during follow-up

- Any medical condition where beta blocker treatment is indicated according to the
treating physician